Phase 3 N=1,961 TAC Versus TC for Adjuvant Breast Cancer
Breast Cancer
Primary: 3-year Invasive Disease-free Survival (IDFS) Among Analyzed ITT Patients — 91.1; 93.2 percentage of participants — p=0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=37 A Study of Gemcitabine Plus Nab-paclitaxel With or Without FG-3019 in Participants With Locally Advanced, Unresectable Pancreatic Cancer
Pancreatic Cancer (Unresectable)
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 24; 12; 9; 6 Participants
Phase 3 N=479 Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma
Anaplastic Ependymoma · Brain Ependymoma · Cellular Ependymoma
Primary: Event-free Survival (EFS) in Children Who Have Completely Resected Ependymoma or Achieved CR and Are Treated With Post-radiation Maintenance Chemotherapy or…
Phase 1 N=20 A Treatment Study for Premenstrual Syndrome (PMS)
Premenstrual Syndrome · Menstruation Disturbances
Primary: Mean Beck Depression Inventory Score — 2.6; 3.0; 5.3; 3.6 score on a scale
N/A N=78 Nitrous Oxide for Identifying the Intersegmental Plane in Segmentectomy: A Randomized Controlled Trial
Pulmonary Nodule, Solitary · Pulmonary Nodule, Multiple · Lung Cancer
Primary: The Intersegmental Border Appearance Time During the Surgery — 320.20; 552.39; 968.33 seconds
Phase 2 N=861 A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia
Chronic Kidney Disease
Primary: Urinary Albumin to Creatinine Ratio (uACR) (mg/g) Change From Baseline at 6 Months (Visit 8), Repeated Measures Mixed Model (MMRM) — 0.8300; 1.043; 0.8369; 0.8499 mg/g…
N/A N=357 The Sub-Saharan Africa Regional Partnership for Mental Health Capacity Building
Depression
Primary: Fidelity in Depression Screening: Number of Screening-eligible Visits at Which Depression Screening is Completed — 14712; 15888 Visits — p=0.836
N/A N=150 Low-Carbohydrate Dietary Pattern on Glycemic Outcomes Trial
Diabetes · PreDiabetes · Metabolic Disease
Primary: Change in Hemoglobin A1c — -0.26; -0.04 percentage — p=<0.05
N/A N=23 Continuous Glucose Monitoring in Diabetes and Prediabetes
Diabetes Mellitus, Type 2 · PreDiabetes · Obesity
Primary: Percent Change in BMI From Baseline to 14 Weeks — -0.3; -0.2 % change over 14 weeks
N/A N=756 Pap Smear Collection With the Papette Brush
Cervical Cancer Screening
Primary: Specimen Adequacy — 335; 371 Participants — p=.75
Phase 3 N=115 Efficacy of SENS 401 in Subjects With Severe or Profound Sudden Sensorineural Hearing Loss
Severe Sudden Sensorineural Hearing Loss
Primary: Change in Pure Tone Audiometry PTA (dB) (Average of the Hearing Threshold of the 3 Contiguous Most Affected Hearing Frequencies in dB as Identified at Study Entry) From…
Phase 3 N=27 Lactobacillus Probiotic for Prevention of UTI
Urinary Tract Infections (UTI's)
Primary: UTI Incidence as Described Below, Over the 16 Week Study Period Following Randomization, in the LACTIN-V Treatment Group (Group A) as Compared to the Placebo Group…
Phase 2 N=40 Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older Patients
Acute Myeloid Leukemia
Primary: Maximal Tolerable Dose of Pembrolizumab for Cohort 1 — 200 mg
N/A N=100 Cerebral Oxygenation in Total Hip Arthroplasty Patients
Cerebral Oxygen Desaturation · Post-operative Delirium
Primary: Oxygen Desaturation Incidences — 4 Participants
N/A N=271 Positive Psychotherapy for Smoking Cessation Enhanced With Text Messaging: A Randomized Controlled Trial
Smoking Cessation
Primary: 7-day Point Prevalence Smoking Abstinence at 12 Weeks — 29; 25 Participants — p=0.71